Should I buy or sell Better Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTTX shares. View BTTX analyst ratings or view top-rated stocks .

What is Better Therapeutics' stock price target for 2024?

2 brokers have issued twelve-month target prices for Better Therapeutics' shares. Their BTTX share price targets range from $3.00 to $9.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 62,400.0% from the stock's current price. View analysts price targets for BTTX or view top-rated stocks among Wall Street analysts .

How have BTTX shares performed in 2024?

Better Therapeutics' stock was trading at $0.1950 at the start of the year. Since then, BTTX shares have decreased by 95.1% and is now trading at $0.0096. View the best growth stocks for 2024 here .

Are investors shorting Better Therapeutics?

Better Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,560,000 shares, an increase of 20.2% from the February 29th total of 2,130,000 shares. Based on an average daily volume of 6,410,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 8.3% of the company's shares are sold short. View Better Therapeutics' Short Interest .

When is Better Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BTTX earnings forecast .

How do I buy shares of Better Therapeutics?

Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BTTX

Better Therapeutics (BTTX) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free BTTX Stock Alerts

$0.0093

0.00 (-6.06%)

(As of 03:58 PM ET)

Compare

Today's Range: $0.0078
▼
$0.0118
50-Day Range: $0.01
▼
$0.22
52-Week Range: $0.01
▼
$1.55

Volume: 254,839 shs
Average Volume: 5.81 million shs
Market Capitalization: $463,698.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Get Better Therapeutics alerts:

Better Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 62,400.0% Upside
$6.00 Price Target
Short Interest: Bearish
8.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.26
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.86) to ($0.56) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.26 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Better Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Better Therapeutics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.29% of the float of Better Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Better Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Better Therapeutics has recently increased by 20.19%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Better Therapeutics does not currently pay a dividend.
Dividend Growth
Better Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BTTX.

3.5

News and Social Media Coverage

News Sentiment
Better Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Better Therapeutics this week, compared to 1 article on an average week.
Search Interest
78 people have searched for BTTX on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Better Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Better Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
51.40% of the stock of Better Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 34.00% of the stock of Better Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Better Therapeutics are expected to grow in the coming year, from ($0.86) to ($0.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Better Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Better Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Wall Street Star

This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

About Better Therapeutics Stock (NASDAQ:BTTX)

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

BTTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BTTX Stock News Headlines

April 10, 2024 | msn.com

Precision Combination Therapy Better Controls High-Risk Subtypes of B-ALL in Mouse Models

March 16, 2024 | uk.investing.com

Better Therapeutics plans employee layoffs, strategic review

April 16, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

March 14, 2024 | markets.businessinsider.com

Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views

March 14, 2024 | businesswire.com

Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq

March 5, 2024 | businesswire.com

Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

March 4, 2024 | finance.yahoo.com

Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

February 22, 2024 | finance.yahoo.com

CAH Feb 2024 107.000 put

April 16, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

February 20, 2024 | benzinga.com

Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

February 20, 2024 | marketwatch.com

Better Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy Platform

February 20, 2024 | businesswire.com

Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

February 6, 2024 | markets.businessinsider.com

Buy Rating on Astria Therapeutics Supported by STAR-0215’s Promising Market Potential and Favorable Trial Results

February 6, 2024 | marketwatch.com

Better Therapeutics Enters Rebate Agreement with Pharmacy Benefit Manager

February 6, 2024 | finance.yahoo.com

Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment

January 18, 2024 | finance.yahoo.com

David Perry Bought 8.6% More Shares In Better Therapeutics

January 17, 2024 | finance.yahoo.com

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

January 16, 2024 | tmcnet.com

Biora Therapeutics Provides Outlook for 2024

January 3, 2024 | finance.yahoo.com

Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings

January 2, 2024 | msn.com

Better Therapeutics applies for FDA breakthrough designation for NASH device

January 2, 2024 | finance.yahoo.com

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

December 13, 2023 | msn.com

Better Therapeutics files to sell 20M shares of common stock for holders

December 12, 2023 | msn.com

Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?

November 29, 2023 | msn.com

Better Therapeutics amends debt facility, implements cost-saving measures

November 28, 2023 | finance.yahoo.com

Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions

November 14, 2023 | finance.yahoo.com

Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award

November 12, 2023 | finance.yahoo.com

Better Therapeutics, Inc. (NASDAQ:BTTX) Q3 2023 Earnings Call Transcript

See More Headlines

Receive BTTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:BTTX
CUSIP: N/A
CIK: 1832415
Web: mcacquisition.com
Phone: 415-887-2311
Fax: N/A
Employees: 54
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $9.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +59,900.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,760,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -217.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.57
Quick Ratio: 0.57

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.04) per share
Price / Book: -0.25

Miscellaneous

Outstanding Shares: 49,860,000
Free Float: 24,233,000
Market Cap: $498,600.00
Optionable: Optionable
Beta: 2.15

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. David P. Perry M.B.A. (Age 56)
Co-Founder & Executive Chairman
Comp: $260k
Mr. Frank L. Karbe (Age 56)
CEO, Interim CFO, President & Director
Comp: $533.37k
Dr. Mark A. Berman M.D. (Age 48)
Chief Medical Officer
Comp: $573.75k
Ms. Kristin Wynholds (Age 51)
Chief Product Officer
Comp: $519.07k
Mr. Andres Camacho
Senior VP of Technology & Head of Engineering
Ms. Angela Willis
Senior Vice President of Market Access
Ms. Jessica Meng
Chief Commercial Officer
Leslie Miller
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BTTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Better Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTTX shares.
View BTTX analyst ratings or view top-rated stocks.
What is Better Therapeutics' stock price target for 2024?: 2 brokers have issued twelve-month target prices for Better Therapeutics' shares. Their BTTX share price targets range from $3.00 to $9.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 62,400.0% from the stock's current price.
View analysts price targets for BTTX or view top-rated stocks among Wall Street analysts.
How have BTTX shares performed in 2024?: Better Therapeutics' stock was trading at $0.1950 at the start of the year. Since then, BTTX shares have decreased by 95.1% and is now trading at $0.0096.
View the best growth stocks for 2024 here.
Are investors shorting Better Therapeutics?: Better Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,560,000 shares, an increase of 20.2% from the February 29th total of 2,130,000 shares. Based on an average daily volume of 6,410,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 8.3% of the company's shares are sold short.
View Better Therapeutics' Short Interest.

When is Better Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BTTX earnings forecast.
How do I buy shares of Better Therapeutics?: Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTTX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial